GlobeNewsWire
04 Aug 2026, 00:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Regeneron's Phase 3 clinical trial of Fianlimab in combination with Libtayo for melanoma failed to reach statistical significance for its primary endpoint of progression-free survival. — The failure of a 'potential blockbuster' drug candidate directly removes a significant future revenue stream and caused an immediate $11 billion market cap loss.
-0.90Regeneron is facing a securities class action lawsuit alleging the company made false and misleading statements about the trial's progress and intentionally delayed disclosing protocol changes. — Legal action introduces additional financial liability and regulatory risk, while damaging investor trust in management's transparency.
-0.40Which stocks this story touches
The company faces a securities class action lawsuit following the failure of a Phase 3 clinical trial and a $11 billion loss in market capitalization.
Continue reading
6 related stories
Search tags
Investors are urged to contact a law firm after the stock plunged due to allegedly misleading financial statements.
Investors are urged to contact a law firm after the stock plunged due to allegedly misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
4h ago
